TICKERNERD
Menu
AVTXAVTXHealthcare · Biotechnology

AVTX Stock Forecast: Avalo Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$16
−6.17% on the day

The 14 Wall Street analysts covering Avalo Therapeutics, Inc. hold a median 12-month price target of $41 — +151.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 38 of 100 as at 12 Sept 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$864.5M
Ticker Nerd rank
38 / 100
Median analyst target
$41
Analysts covering
14
Revenue$0.0
Operating income−$31.5M
Net income−$36.4M
Free cash flow−$20.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−15.2%
1M
−17.2%
YTD
−11.2%
1Y
+48.2%
From 52W high
−29.5%
From 52W low
+65.2%
$10
$23
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

AVTX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Avalo Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
38 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
83
Quality
65
Size
47
Value
45
Accruals
45
Growth
44
Revisions
38
Volatility
28
Issuance
25

Momentum (83): The shares have been drifting up relative to others.

Issuance (25): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

AVTX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on AVTX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$20$30$40$50$60Oct 25Jan 26Apr 26Jul 26AVTXHigh $60Median $41Low $30

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says14 analysts
14 Buy0 Hold0 Sell
Low $30Median $41High $60

The green dot is the last close — the median target sits +151.2% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
7 Aug 2026GuggenheimMaintainsBuy$50 → $48
7 Aug 2026HC Wainwright & Co.MaintainsBuy$35 → $30
6 July 2026Leerink PartnersInitiatesOutperform$38
6 July 2026Leerink PartnersInitiatesOutperform—
16 June 2026BTIGReiteratesBuy—
12 June 2026B of A SecuritiesInitiatesBuy—
14 May 2026CitizensMaintainsMarket Outperform—
14 May 2026HC Wainwright & Co.MaintainsBuy—
14 May 2026MizuhoMaintainsOutperform—
14 May 2026WedbushMaintainsOutperform—
11 May 2026Piper SandlerMaintainsOverweight—
6 May 2026BTIGMaintainsBuy—
6 May 2026CitizensMaintainsMarket Outperform—
6 May 2026WedbushMaintainsOutperform—
13 Apr 2026BTIGReiteratesBuy—
9 Apr 2026Wolfe ResearchInitiatesOutperform—
6 Apr 2026CitizensInitiatesMarket Outperform—
25 Mar 2026HC Wainwright & Co.MaintainsBuy—
24 Mar 2026BTIGReiteratesBuy—
2 Feb 2026GuggenheimInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. AVTX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

AVTX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Avalo Therapeutics, Inc. returned +48.2% against +17.5% for the S&P 500, dividends included.

AVTX vs S&P 500, last 12 monthsTotal return, rebased to 100
100120140160180200Oct 25Jan 26Apr 26Jul 26AVTXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

AVTX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
3
Fundamentals

Avalo Therapeutics, Inc. (AVTX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
2.3×

Cheaper than 69% of US stocks

Price / sales
14652.8×

Cheaper than 1% of US stocks

Price / book
1.9×

Cheaper than 47% of US stocks

EV / EBITDA
−5.1×

Cheaper than 79% of US stocks

Growth & margins
Revenue growth (YoY)
−100.0%

Higher than 1% of US stocks

Earnings growth (YoY)
—
Gross margin
—
Operating margin
−154847.5%

Higher than 1% of US stocks

Net margin
100.0%

Higher than 99% of US stocks

Returns & dividend
Return on equity
−36.3%

Higher than 25% of US stocks

Return on assets
−18.5%

Higher than 21% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Avalo Therapeutics, Inc. (AVTX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Avalo Therapeutics, Inc. has a market value of $864.5M and an enterprise value of $464.5M.

  • Revenue in the twelve months to 30 June 2026: $59K. The latest quarter shrank 100.0% year on year.

  • Net income over the same four quarters: −$100.3M, a −170055.9% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$68.3M.

  • Shares outstanding: 52.9M.

  • Trailing P/E: 2.3×; forward P/E: −5.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Avalo Therapeutics, Inc. employs 33 people — $2K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

AVTX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
AVTXAvalo Therapeutics, Inc.$864.5M
38
TBPHTheravance Biopharma, Inc.$856.6M
89
IMMXImmix Biopharma, Inc.$864.2M
34
GERNGeron Corp.$864.7M
52
ARDXArdelyx, Inc.$869.8M
50
RIGLRigel Pharmaceuticals, Inc.$874.0M
77
CLYMClimb Bio, Inc.$816.0M
60

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Avalo Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest AVTX news & analysis

Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 4 Sept 2026neutral

Avalo Therapeutics announced that its Compensation Committee approved inducent equity awards, consisting of nonstatutory stock options to purchase an aggregate of 78,000 shares of common stock, granted to six new employees. The grants were made as inducements material to the employees joining the company, in accordance with Nasdaq Listing Rule 5635(c)(4).

Why it matters — AVTX watchers would care because the inducement equity grants signal the company's hiring and talent-acquisition activity, a routine corporate action that could result in modest share dilution.

Avalo Therapeutics: Phase 2 Validation Has Created An IL-1β Franchise

Seeking Alpha · 4 Sept 2026positive

Seeking Alpha reports that Avalo Therapeutics has advanced into a registrational-stage, well-funded biotech following validated Phase 2 data for abdakibart in hidradenitis suppurativa, showing statistically significant HiSCR75 response rates and clean safety with monthly dosing. The company holds a $472M cash position supporting operations into 2029.

Why it matters — AVTX watchers would care because validated Phase 2 efficacy and a significant cash runway may position the company for Phase 3 development with reduced near-term dilution risk.

Avalo Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewsWire · 3 Sept 2026neutral

Avalo Therapeutics announced that its management will participate in upcoming investor conferences. The announcement was made on September 3, 2026, from its headquarters in Wayne, Pennsylvania, and did not specify which conferences.

Why it matters — Avalo Therapeutics watchers would care because the company's management participation at investor conferences could provide additional visibility and opportunities for investors to learn more about the company's IL-1β pathway programs.

Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Updates

GlobeNewsWire · 6 Aug 2026neutral

Avalo Therapeutics, Inc., a clinical-stage biotechnology company focused on IL-1β pathway therapeutics for immune-mediated inflammatory diseases, announced its business updates and financial results for the second quarter of 2026 on August 6, 2026.

Why it matters — For those tracking AVTX, the release provides an official update on the company's recent business activities and second-quarter 2026 financial position.

FAQ

Frequently asked questions about AVTX stock

What is the AVTX stock price forecast for 2026-2027?

The 14 Wall Street analysts covering Avalo Therapeutics, Inc. have a median 12-month price target of $41, with estimates ranging from $30 to $60. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is AVTX stock a buy right now?

Of the 14 analysts covering Avalo Therapeutics, Inc., 14 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Avalo Therapeutics, Inc. 38 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank AVTX?

As at 12 Sept 2026, Avalo Therapeutics, Inc. ranks 38 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (83 of 100).

Will AVTX stock go up?

No one can know that. What the data says: the median 12-month target from 14 analysts implies +151.2% from the last close, and Ticker Nerd's factor model ranks Avalo Therapeutics, Inc. 38 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the AVTX stock forecast for 2030?

No analyst covering Avalo Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AVTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $30 to $60 over the next 12 months.

How has AVTX stock performed over the past year?

Avalo Therapeutics, Inc. returned +48.2% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Avalo Therapeutics, Inc. do?

Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for immune-mediated inflammatory diseases.

What is the latest news on AVTX?

The most recent item we track (GlobeNewsWire, 4 Sept 2026): "Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)". Avalo Therapeutics announced that its Compensation Committee approved inducent equity awards, consisting of nonstatutory stock options to purchase an aggregate of 78,000 shares of common stock, granted to six new employees. The grants were made as inducements material to the employees joining the company, in accordance with Nasdaq Listing Rule 5635(c)(4).

Company

About Avalo Therapeutics, Inc.

Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for immune-mediated inflammatory diseases. The company’s current work centers on IL-1β-based treatments, with Abdakibart (AVTX-009) as its lead asset, an anti-IL-1β monoclonal antibody designed to address inflammatory conditions. Avalo Therapeutics also maintains a pipeline that includes additional immune-focused programs, reflecting its emphasis on targeting dysregulated inflammation through biologic therapies. Based in Wayne, Pennsylvania, and incorporated in 2011, the company operates within the immunology and inflammation space, where its products are aimed at diseases with significant unmet medical need.

CEO Dr. Garry A. Neil M.D. · 33 employees · United States · https://www.avalotx.com